Reversion and rereversion in ras-transformed cells.
Marshall
C J
CJ
Institute of Cancer Research, Chester Beatty Laboratories, Royal Cancer Hospital, London, England.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002461:Cell Line, Transformed; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D002472:Cell Transformation, Viral; D006224:Cricetinae; D003412:Cricetulus; D005347:Fibroblasts / Q000166:cytology; D020558:GTP Phosphohydrolases / Q000235:genetics* / Q000502:physiology; D019204:GTP-Binding Proteins / Q000235:genetics* / Q000502:physiology; D005800:Genes, Fungal; D016147:Genes, Tumor Suppressor; D011905:Genes, ras; D006801:Humans; D006822:Hybrid Cells / Q000378:metabolism; D051379:Mice; D009154:Mutation; D015689:Oncogene Protein p21(ras) / Q000235:genetics* / Q000502:physiology; D010641:Phenotype; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics* / Q000502:physiology; D012441:Saccharomyces cerevisiae / Q000235:genetics; D013489:Suppression, Genetic
D000911:Antibodies, Monoclonal; D020558:GTP Phosphohydrolases; D019204:GTP-Binding Proteins; C501009:HRAS protein, human; D015689:Oncogene Protein p21(ras); D016283:Proto-Oncogene Proteins p21(ras)